GlassScriptPhysician profile
Jeffrey P Allerton
NPI 1205886181
$68,968.70
in general payments reported to CMS, 2019-2025
36 companies · $593 in 2025
The $593 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $27K · 2021: $20K · 2022: $7,475 · 2023: $602 · 2024: $52.19 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,124 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,124.25 |
| Education | $122.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $66,000.00 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $287.59 | 2021-2025 | |
| Astellas Pharma US INC | $287.49 | 2021-2023 | Padcev |
| Seagen INC. | $221.16 | 2021-2022 | |
| Pfizer INC. | $207.33 | 2020-2024 | |
| E.R. Squibb & Sons, L.L.C. | $171.65 | 2023 | Reblozyl, Opdualag, Opdivo |
| Regeneron Healthcare Solutions, INC. | $171.42 | 2021-2022 | |
| Celgene Corporation | $165.31 | 2021-2023 | Reblozyl, Opdualag |
| Merck Sharp & Dohme LLC | $163.02 | 2020-2025 | Keytruda, Lynparza |
| Genzyme Corporation | $142.97 | 2021-2025 | |
| Aveo Pharmaceuticals, INC. | $122.14 | 2025 | |
| Incyte Corporation | $116.33 | 2022-2025 | Jakafi |
| Daiichi Sankyo INC. | $93.09 | 2022-2025 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $88.52 | 2022-2025 | Enhertu |
| Epizyme, INC. | $82.95 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $82.65 | 2021-2023 | Verzenio, Retevmo, Jaypirca |
| Eisai INC. | $74.97 | 2021-2024 | |
| Emd Serono, INC. | $57.31 | 2020-2022 | |
| Iovance Biotherapeutics, INC. | $48.13 | 2025 | Amtagvi |
| Janssen Biotech, INC. | $43.69 | 2022-2023 | |
| Pharmaessentia USA Corporation | $28.23 | 2025 | Besremi |
| Adaptive Biotechnologies Corporation | $28.02 | 2025 | Clonoseq |
| Amgen INC. | $25.54 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.17 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.64 | 2022 | |
| Exelixis INC. | $24.40 | 2021 | |
| Apellis Pharmaceuticals, INC. | $22.88 | 2023 | Empaveli |
| Novocure INC. | $22.16 | 2025 | Optune Gio |
| Beigene USA, INC. | $20.40 | 2022 | |
| Puma Biotechnology, INC. | $19.96 | 2021 | |
| Gilead Sciences, INC. | $19.58 | 2021 | |
| Tersera Therapeutics LLC | $18.78 | 2023 | Zoladex |
| Ipsen Biopharmaceuticals, INC | $16.90 | 2023 | Tazverik |
| Servier Pharmaceuticals LLC | $16.20 | 2021 | |
| Morphosys, US INC. | $14.40 | 2022 | |
| Array Biopharma INC | $13.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Allerton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.